Abstract 326P
Background
Exercise is suggested to reduce the recurrence risk in individuals with breast cancer. Evidence regarding relevant physiological mechanisms remains scarce. Here, we examined the association of inflammatory biomarkers with predicted recurrence events.
Methods
The Optitrain randomized controlled trial consisted of 240 patients undergoing chemotherapy for primary breast cancer randomised to interventions entailing biweekly supervised concurrent resistance exercise and high-intensity interval training (RT-HIIT), or concurrent aerobic exercise and HIIT (AT-HIIT), or usual care (UC) between 2013-2016. At baseline and the one-year follow-up, 96 inflammatory protein biomarkers were assessed using the Olink® Proximity Extension Assay Oncology Panel. Group differences were estimated using analysis of covariance adjusted for baseline levels. Recurrence outcomes were obtained from National Swedish registers. Event probabilities were predicted from cox-proportional hazards models adjusted for age, menopause, BMI, tumour characteristics, and taxane treatment. Associations between survival probabilities and inflammatory markers were examined using Pearson’s correlation.
Results
When comparing RT-HIIT and UC, exploratory differences across several C-C-motif chemokine ligands were found (CCL2, CCL3, CCL4, CCL13, CCL20, CCL23). Moreover, DCN, ICOSLG, soluble CD8 and CD4, CX3SL1, CXCL10, CD70, CD83, CSF-1, HGF, NCR1, PD-L2, PIGF, PTN, TNFRSF12A, and TNFRSF21S differed across groups (p<0.2). When examining event probabilities, CD70, soluble CD4, CCL2, CCL3, CCL4, CCL13, CCL20, and CCL23 at the one-year follow-up examinations formed a cluster of a weakly increased risk in recurrence-related events. The strongest associations between event probabilities and biomarkers of inflammation were recorded for distant recurrence-free interval events.
Conclusions
Explorative analyses assessing the interplay of systemic inflammation, exercise, and predicted event probabilities suggested a cluster of inflammatory biomarkers affected by exercise and positively correlated with recurrence-related predicted event probabilities.
Clinical trial identification
NCT02522260, August 13, 2015.
Editorial acknowledgement
Legal entity responsible for the study
Region Stockholm.
Funding
1. The Swedish Cancer and Traffic Accident Foundation (CTRF) (grant number F-C-001225) 2. Swedish Cancer Foundation (grant number 130452) 3. Radiumhemmet Research foundation (grant number 131242) 4. Karolinska Institutet School of Caring Sciences (grant number 04960/2012).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
291P - Multi-center investigation of a detection model utilizing cfDNA for early-stage breast cancer screening
Presenter: Chao Ni
Session: Poster session 14
292P - Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2– early breast cancer (EBC) from US electronic health records (EHR)
Presenter: Komal Jhaveri
Session: Poster session 14
293P - Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
Presenter: Luc Cabel
Session: Poster session 14
294P - Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer
Presenter: Sung Gwe Ahn
Session: Poster session 14
295P - Long-term clinical outcomes and treatment strategy considerations by ER expression level in breast cancer
Presenter: Yumi Wanifuchi-Endo
Session: Poster session 14
296P - Investigating survival by breast cancer molecular subtype in Australia: A population-based study
Presenter: Larissa Vaz-Goncalves
Session: Poster session 14
297P - Real-world data on prognostication of early stage breast cancer patients using CanAssist Breast- first immunohistochemistry based prognostic test developed and validated on Asians
Presenter: Vashista Maniar
Session: Poster session 14
Resources:
Abstract
298P - Enhancing prognostic accuracy for breast adenoid cystic carcinoma using machine learning models
Presenter: Sakhr Alshwayyat
Session: Poster session 14
Resources:
Abstract
299P - Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer
Presenter: Jitnarong Karnmanee
Session: Poster session 14
300P - Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up
Presenter: Julia Tutzauer
Session: Poster session 14